Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
  • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
  • G01N33/571—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses for venereal disease, e.g. syphilis, gonorrhoea
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the present invention generally relates to the use of recombinant DNA technology to create a microorganism capable of producing antigens reactive with antibodies developed in response to Treponema pallidum.
• the production, by genetically engineered microorganisms, of the immunodominant 47-48 kilodalton surface, antigen of Treponema pallidum, generally referred to as the 47 kilodalton surface antigen, is a particular object of the present invention.
• Treponema pallidum Infection by Treponema pallidum is the well-established cause of syphilis. Syphilis, despite the continued availability of effective antibiotics, continues to result in worldwide misery and morbidity. The inability to establish in vitro cultures of Treponema pallidum has restricted research studies of this organism. This microorganism is usually propagated by in vivo culture in hamster lymph nodes or rabbit testes, which are useful but not methods conducive to large-scale production of Treponema pallidum or the antigens thereof, particularly pure antigens. It has proven difficult to obtain Treponema pallidum antigens free of hamster or rabbit antigens from Treponema pallidum cultured in vivo. Thus, purified treponemal antigens have not been available from traditional techniques of microorganism production.
• Treponema pallidum antigens More modern techniques of molecular biology have been applied in relation to characterization and detection of Treponema pallidum, Treponema pallidum antigens and infection by Treoonema pallidum.
• Various polyclonal and monoclonal antibodies to Treponema pallidum antigens have also been prepared.
• Rabbit anti-T. pallidum serum was used in a radioimmuno-colony blot assay to detect E. coli clones synthesizing T. pallidum antigens.
• One clone was found to encode a gene product of 44kDa.
• Either immune rabbit serum or human syphilitic serum was used to detect the E. coli. clones producing the T. pallidum antigen.
• the methodological difference between this reference and the present disclosure begins to distinguish the present invention. Additionally, it has been found that monoclonal antibodies specific for the T. pallidum 4 kDa surface antigen were unable to react with the 44kDa antigen.
• T. pallidum DNA was cleaved with Bam HI endonucleus and the cleavage fragments ligated to Bam HI- cleaved plasmid pBR322.
• Four transformed E. coli clones were noted as generally producing T. pallidum antigens.
• Stamm et al. (1983) (Infect, and Immuno., V 41, pp 709-721) described the expression of Treponema pallidum Antigens in Escherichia coli K-12. Stamm et al. (1983) describe use of a pBR322 bank of recombinant plasmids harboring Treponema pallidum DNA inserts in Escherichia coli and identification of clones expressing Treponema pallidum antigens.
• the molecular weights of antigens produced by plasmid pLV32-transformed E. coli. were 25 kDa, 35 kDa and 39 kDa in size.
• E. coli transformants were noted producing a variety of T. pallidum polypeptide antigens, including polypeptides with apparent sizes of 35 kDa, 41 kDa, 44 kDa, and 58 kDa, among others.
• Fehniger et al. (1985) (Abstracts of the 85th Annual Meeting of Amer. Soc. for Microbiol., Abstract B156, p 44) described a 38 kDa hydrophobic T. pallidum antigen as produced by an E. coli transformed with a recombinant plasmid.
• Rodgers et al., (1985) (Abstracts of the 85th Annual Meeting of Amer. Soc. for Microbiol., Abstract C30, p 305) described evaluation of the reactivity of a 37 kDa polypeptide T. pallidum antigen produced by an E. coli transformant.
• PCT patent application (1984) number PCT/US83/01718 International Publication Number WO84/01961 entitled "Recombinant DNA Derived Antigens of Treponema Pallidum” by Lovett) described E. coli transformant clones containing plasmid-bound T. pallidum DNA and expressing T. pallidum peptide antigens.
• Various clones produced antigens with molecular weights or weight ranges of: 16- 20 kDa; 43 kDa; 37-46 kDa; 18-23 kDa; 150 kDa; or 180 kDa.
• the 47 kDa antigen was shown to be: (i) surface-associated; (ii) abundant (Jones et al., (1984) J. Exp. Med., V 160, pp 1404-1420; Marchitto et al. (1984) Infect. Immun., V 45, pp 660-666; and Marchitto et al. (1986) Infect. Immun., V 51, pp 168-176); (iii) highly immunogenic in both rabbits and humans (Baker-Zander et al. (1985) J. Infect. Pis., V 151, pp 264-272; Hanff et al. (1982) J. Immunol., V 129, pp 1287-1291; Jones et al. (1984) J. Exp. Med., V 160, pp 1404-1420; Lukehart et al. (1986) Sex. Trans. Dis.,
• Anti-47 kDa mAbs possess diagnostic value; they bind strongly in immunofluorescence assays to T. oallidum isolated from human syphilitic lesions. Anti-47 kDa mAbs also partially block the attachment of T. pallidum to host cells in vitro (Jones et al., (1984) J. EXP. Med., V 160, pp 1404-1420). Anti-47 kDa mAbs bind to T. pallidum in the T.
• TPI pallidum immobilization
• T. pallidum contains an immunodominant, 47 kPa major outer membrane protein. Additionally, our earlier findings (Marchitto et al. (1986) Infect. Immun., V 51, pp 168-176; and Norgard et al. (1984) J. Clin. Microbiol., V 20, pp 711-717) that anti-47 kDa mAbs can be used diagnostically to detect relatively few T. pallidum has been confirmed by Lukehart et al. (Lukehart et al. (1985) J. Immunol., V 134, pp 585-592) and Hook et al. (Hook et al. (1985) J.
• Hook et al. (Lukehart et al. (1986) Sex. Trans. Pis., V 13, pp 9-15) also reported a correlation between early immune clearance of infecting T. pallidum and healing of the primary lesion in the experimental rabbit; it was postulated that primary lesion healing may be influenced by antibody directed against immunodominant molecules, such as the 47 kPa immunogen
• pallidum immunogen may possess "pathogen- specific" determinants may be located on separate polypep tides which co-migrate in polyacrylamide gels. When either a 3.85 kb Hindlll DNA fragment of the 5.4 kb encoding sequence or intact hybrid plasmid DNA (containing the entire 5.4 kb encoding sequence) were used as DNA hybridization probes under moderate or low DNA hybridization stringency, no hybridization with any homologous DNA fragment of the nonpathogenic treponemes was observed.
• mAb C2-1 of Lukehart directed against a "common" treponemal epitope of a 47 kDa immunogen (Hook et al. (1985) J. Clin. Microbiol., V 22, pp 241-244; and Lukehart et al. (1985) J. Immunol., V 134, pp 585-592), failed to react with the 47 kDa immunogen-expressing clones of the present invention, while the pathogen-specific mAb H9-1 (Hook et al. (1985) J. Clin. Microbiol., V 22, pp 241-244, Lukehart et al. (1985) J. Immunol., V 134, pp 585-592) reacted with these clones.
• genetic and immunologic data provided here support the existence of a pathogen-specific 47 kDa immunogen.
• T. pallidum 47 kDa immunogen gene in Escherichia coli is described herein as a component of the present invention.
• the contents of the above-described references are incorporated by reference herein for their descriptions of microorganisms, materials and methods established in the field.
• Monoclonal antibodies directed against the 47 kDa major outer membrane surface immunogen of virulent Treponema pallidum were used to select E. coli recombinant clones expressing the 47 kDa immunogen.
• the phenotype of the clones was dependent on the presence of recombinant plasmid in the host cell.
• Southern hybridization revealed that the cloned T. pallidum DNA sequence was an accurate representation of the T. pallidum genomic DNA arrangement. Purified IgG from rabbits experimentally infected with T. pallidum or human secondary syphilitic sera specifically reacted with the clones while normal human serum or IgG from normal rabbit serum did not. Results of Southern hybridization indicated that a homologous 47 kDa immunogen gene was absent in at least 4 species of nonpathogenic treponemes tested, as well as from total rabbit genomic
• FIG. 1 Radioimmuno-colony blot assay of E. coli recombinant PNA clone colonies expressing the 47 kPa surface immunogen of T. pallidum. T. pallidum cells (lan 1) were spotted onto each filter as a positive control. Negative control clones included pMN7 (lane 2) and pBR322 in E. coli RR1 (lane 3). Filters were reacted with mAbs
• FIG. 2 Partial restriction enzyme map of the 5.4 kb insert of pMN23 encoding the 47 kPa immunogen of T. pallidum.
• the EcoRI site of pBR322 is located to the right of the figure.
• the direction of transcription for the 47 kPa antigen gene appears to be from left to right, opposite that of the beta-lactamase gene.
• the insert is flanked by Pstl sites just outside short GC tails, and possesses a 3 . 85 kb internal Hindl ll f ragment .
• FIG. 3 Southern blot hybridization of Hindlll- restricted genomic DNAs and recombinant plasmid pMN23 encoding the 47 kPa immunogen of T. pallidum.
• Panel A 1% agarose gel containing HindiII-restrieted genomic PNA of rabbit (lane 2), T. pallidum (lane 3), T. denticola (lane 4), T. phaqedenis (lane 5), T. scoliodontum (lane 6), T. vincentii (lane 7), recombinant plasmid pMN23 (lane 8), and plasmid pBR322.
• Lanes 1 and 10 contain combined pBR322-AluI and bacteriophage lambda-HindiII molecular weight markers.
• B Southern Blot of Panel A; a fragment of plasmid PNA from clone pMN23 was used as the labeled hybridization probe. Note the presence of the 3.85 kb homologous PNA Hindlll-fragment present only in T. pallidum genomic PNA (lane 3) and the recombinant plasmid pMN23 (lane 8).
• FIG. 4 Radioimmunoprecipitation of the 47 kPa immnuurnogen of T. pallidum from 125 I-labeled T. pallidum and
• FIG. 5 Western blot of the 47 kPa immunogen expressed by recombinant clones pMN23 and pMN24. Solubilized antigens were detected after gel electrophoresis and protein transfer by incubation with anti-47 kPa mAb8G2, which produced its characteristic reactivity profile with the 47 kPa T. pallidum immunogen (lane 1). Lanes 2 and 3 contained the 47 kDa immunogen-expressing clones pMN23 and pMN24, respectively. Lanes 4, 5, and 6 contained the 34 kDa immunogen-expressing clone pMN20, pBR322 in E. coli RR1, and the 44 kDa immunogen-expressing clone pMN7, respectively, as negative controls.
• the present invention involves the use of a clone bank produced by conventional recombinant DNA techniques involving insertion of Treponema pallidum DNA fragments into a suitable vector and transferring the DNA fragments into a microorganism recipient.
• a clone bank comprising Treponema pallidum DNA
• clone bank described by the inventor was used as a preferred source of recombinant E. coli clones (Norgard et al. (1983), Infection and Immunity, 42 435-445). This clone bank of microorganisms was screened for clones producing a particular Treponema pallidum antigen.
• the screening was performed by observing interactions of clone colonies wit antibodies specifically binding to the Treponema pallidum antigen of interest. Clones producing antigen of supplements were selected, separated and propagated to produce Treponema pallidum antigen for further identification, characterization or use. This use may be, for example, in the detection of antibodies to Treponema pallidum or in the production of a vaccine useful for the induction of immunity to syphilis.
• the present invention comprised a process for preparing microbial clones expressing the 47 kPa surface immunogen of Treponema pallidum.
• the PNA of a microbial vector is cleaved, preferably by a restriction endonuclease, to produce a first PNA fragment.
• Said first PNA fragment is combined with a second PNA fragment, the second PNA fragment being from Treponema pallidum.
• Said first and second DNA fragments are characterized as being capable of recombination, and a recombinant vector bearing Treponema pallidum DNA is ligatively formed.
• a suitable microbial host is transfected with said recombinant vector to produce microbial clones expressing Treponema pallidum antigens.
• These microbial clones are then cultivated, preferably on the surface of a nutrient agar, to form visible colonies.
• the colonies are then contacted with an antibody having a specific affinity for the 47 kDa surface immunogen of Treponema pallidum.
• Microbial clone colonies having an affinity for the antibody are then identified and selected. Said selected colonies are characterized by their expression of the 47 kDa surface immunogen of Treponema pallidum.
• the 47 kDa surface immunogen described above may be defined by having a specific affinity for monoclonal antibody produced by murine hybridoma cell line 8G2
• the microbial vector is most preferably a plasmid although other usable vectors such as many phages are well known in the art.
• the most preferred microbial vector is plasmid pBR322.
• the microbial vector is preferably cleaved with Pstl and dG-tailed to form the first DNA fragment.
• a monoclonal antibody as an antibody for identification and selection of clone colonies producing the 47 kDa surface immunogen.
• a most preferred monoclonal antibody is that produced by murine hybridoma cell line 8G2 (American Type Culture Collection number HB8134).
• a microbial host particularly preferred in the practice of this invention is of the species Escherichia coli.
• the second DNA fragment used for the formation of a recombinant vector for the creation of recombinant microorganisms is preferably from a partial restriction enzyme digest of Treponema pallidum or other pathogenic subspecies of Treponema.
• the second DNA fragment is preferably obtained from this partial restriction enzyme digest and tailed with dC residues.
• the recombinant plasmid adapted for transformation of a microbial host and formation of a Treponema pallidum immunogen most preferably comprises a plasmid vector into which a deoxyribonucleic acid (DNA) segment which codes for the 47 kDa surface immunogen of Treponema pallidum has been inserted.
• the transformant microorganisms of the present invention are those which include a recombinant plasmid comprising a plasmid vector into which a DNA segment which codes for the 47 kDa surface immunogen of Treponema pallidum has been inserted.
• the inserted Treponema pallidum DNA segment coding for the 47 kDa surface immunogen is shown as a 5.4 kb partially restriction enzyme-mapped fragment in Figure 2.
• the presence of antibodies to Treponema pallidum in biological fluids may be detected by processes of the present invention.
• a sample of biological fluid is first obtained and then a 47 kDa surface immunogen of Treponema pallidum produced by the recombinant DNA techniques of the present invention are added to the sample of biological fluid. Then, whether said immunogen reacts with antibodies to Treponema pallidum present in said sample may be determined by any of the numerous immunological methods for such determinations well known in the field.
• a process for immunizing individuals against infection by Treponema pallidum is also comprised by the present invention.
• the immunization process comprises obtaining an amount of the 47 kDa surface immunogen of Treponema pallidum from a recombinant microorganism producing said immunogen.
• the next step is to administer said immunogen to an individual in an amount and manner eliciting formation of antibodies or induction of cell-mediated immunity by the individual to the 47 kDa surface immunogen of Treponema pallidum.
• a microorganism of the strain Escherichia coli capable of producing the 47 kDa surface immunogen of Treponema pallidum has been produced by the processes of the present indention and has been deposited with the American Type Culture Collection, Rockville, MD as ATCC Deposit No. 67204.
• This microorganism has an identifying characteristic of being reactive with antibodies to Treponema pallidum, particularly antibody to the 47 kPa surface immunogen of Treponema pallidum.
• a 47 kPa antigen reactive with antibodies to Treponema pallidum and pro Jerusalem by a recombinant microorganism such as the strain of Escherichia coli having the ATCC Peposit No. 67204 is also specifically comprised by the present invention.
• Such 47 kDa recombinant-synthesized antigens identified by molecular mass (size) and immunological characteristics (binding of monoclonal antibodies 8G2 [ATCC No. HB-8134] and 11E3 [Patent No. 4,514,498 and Patent Application Serial No. 702,327]) as the 47 kPa surface immunogen of Treponema pallidum, may be used to prepare unique compositions of matter useful in the diagnosis of or vaccination against pathogenic treponemal infections such as by Treponema pallidum or other pathogenic subspecies of Treponema.
• a process for detecting the presence of Treponema pallidum in a clinical sample may be devised using the nucleotide fragments of the present invention including those coding for the 47 kPa surface immunogen of Treponema pallidum.
• Such nucleotide fragments are included within the 5.4 kb insert of plasmid pMN23 shown in Figure 2. This plasmid has been deposited with the American Type Culture Collection as ATCC Peposit No. 67204. Labeled nucleotide fragments may be prepared directly from the 5.4 kb insert or from complementary nucleotide fragments synthesized from the nucleotide sequences of that insert.
• Said deposited sample is then treated to affix genetic material of any pathogenic Treponema pallidum present in said sample to the support in substantially single stranded form at substantially the same site on the support where said sample was deposited.
• the fixed single stranded genetic material is then contacted with a labeled probe having at least about 25 bases substantially complementary, to a nucleotide sequence of Treponema pallidum coding for the 47 kPa surface immunogen. This contacting is under hybridizing conditions at a predetermined stringency.
• Puplex formation on said support between affixed Treponema pallidum PNA and the labeled probe may be detected by measuring the amount of the label bound to the solid support.
• the Treponema pallidum antigen of particular interest in this invention was the 47 kiloPalton (kPa) surface immunogen previously described (Jones et al. (1984) J. Exp. Med., V 160, pp 1404-1420) and Marchitto et al.
• T. pallidum The virulent Nichols strain of Treponema pallidum subspecies pallidum (T. pallidum) was used as the representative pathogen in this study. It was maintained and cultivated in the testicles of New Zealand white rabbits as previously described (Norgard et al. (1983) Infect. Immun., V 42, pp 435-445 and Robertson et al. (1982) Infect. Immun., V 36, pp 1076-1085).
• E. coli RRl harboring the plasmid pMN7 (old designation: RICB2-1) has been described (Norgard et al. (1983) Infect. Immun., V 42, pp 435-445); pMN7 originated from the clone bank referenced below and it contains a 3.7-kilobase (kb) PNA insert of T. pallidum PNA cloned by GC-tailing into the Pstl site of pBR322. It encodes a 44 kPa recombination antigen unrelated to the 47 kPa antigen.
• kb 3.7-kilobase
• the 44 JcPa antigen of the clone pMN7 is immunoprecipitable by immune rabbit serum (Norgard et al. (1983) Infect. Immun., V 42, pp 435-445) but not by any of our current mAbs.
• Clone pMN20 encoding and expressing a 34 kPa surface antigen of T. pallidum, has been described (Swancutt et al. (1986) Infect. Immun., V 52, pp 110-119). All plasmid derivatives were propagated in E. coli RRl and isolated and purified according to Norgard (Norgard (1981) Anal. Biochem., V 113, pp 34-42). New Zealand White normal male rabbit liver PNA and treponemal PNAs were isolated as previously described (Norgard et al. (1981) Science, V 213, pp 553-555).
• T. pallidum was purified from rabbit testicular tissue by the Percoll density gradient method (Hanff et al. (1984) Sex.
• Southern Gel Hybridizations were performed according to the previously published method (Norgard et al. (1981) Science, V 213, pp 553-555, Southern (1975) J. Mol. Biol., V 98, pp 503-517, (Swancutt et al. (1986) Infect. Immun., V 52, pp 110-119).
• a PNA restriction enzyme fragment was isolated from low melt agarose by Elutip TM (Schleicher & Schuell, Keene,
• Hybridization with PNA probes was carried out in 2X Penhardt's solution (Southern (1975) J. Mol. Biol., V 98, pp 503-517) plus 6X SSC buffer
• filters were washed 3 times (30 min per wash) at room temperature with 500 ml portions of 2X SSC+0 .1% sodium dodecyl sulfate followed by an additional 3 washes at room temperature (30 min per wash) using 500 ml portions of 0.1X SSC+0.1% sodium dodecyl sulfate. Filters were dried and subjected to autoradiography (Laskey (1977) FEBS Lett., V 82, pp 314- 316). Monoclonal Antibodies, Antisera, and Antibody Probes.
• Murine mAbs 8G2 (IgGl), 11E3 (IgG2a), and 3B5 (IgGl) directed specifically against T. pallidum were generated, maintained, and characterized as previously described (Jones et al. (1984) J. Exp. Med., V 160, pp 1404-1420; Marchitto et al. (1984) Infect. Immun., V 45, pp 660-666; Marchitto et al. (1986) Infect. Immun., V 51, pp 168-176; Norgard et al. (1984) J. Clin. Microbiol., V 20, pp 711-717; Robertson et al. (1982) Infect. Immun., V 36, pp 1076-1085; and Swancutt et al. (1986) Infect. Immun.,
• MAb 11E3 has been described in detail (Jones et al. (1984) J. Exp. Med., V 160, pp 1404-1420; Marchitto et al. (1984) Infect. Immun., V 45, pp 660-666; Marchitto et al. (1986) Infect. Immun., V 51, pp 168-176; and Norgard et al. (1984) J. Clin. Microbiol., V 20, pp 711-717).
• MAbs 8G2 and 11E3 are directed against the major 47 kDa immunogen (Jones et al., (1984) J. Exp. Med.,
• MAb 3B5 reacts with a 34 kDa surface immunogen of T. pallidum (Swancutt et al. (1986) Infect. Immun., V 52, pp 110-119).
• MAbs were used within in vitro hybridoma clone supernatants or were affinity purified from hybridoma clone supernatants using individual protein A-Sepharose columns (Ey et al. (1978) Immunochemistrv, V 15, pp 429-436).
• MAbs C2-1 (IgM) and H9-1 (IgGl) were directed against "common” and "pathogen-specific" epitopes of T. pallidum, respectively (Hook et al. (1985) J. Clin. Micro- biol., V 22, pp 241-244, Lukehart et al. (1985) J.
• Radioimmuno-Colony Blot Assay The radioimmuno- colony blot (RICB) assay for the detection of E. coli clone colonies synthesizing T. pallidum antigens was carried out according to Norgard and Miller (Norgard et al. (1983) Infect. Immun., V 42, pp 435-445) with minor modifications (Swancutt et al. (1986) Infect. Immun., V 52, pp 110-119).
• Radioimmunoprecipitation was performed as previously described (Swancutt et al. (1986) Infect. Immun., V 52, pp 110-119) with minor modifications.
• Radioimmuno-precipitation of T. pallidum approximately 5 x 10 6 counts per min of 125 I- labeled treponemes (1-3 counts per min per treponeme) were incubated in 1.0 ml of solubilization buffer (10 mM Tris-
• E. coli recombinant derivatives approximately 1 x 10 8 solubilized E. coli per gel lane were used.
• FIG. 1 shows the results of RICB assays using mAbs.
• MAb 3B5 directed against a 34 kDa surface immunogen of T. pallidum (Swancutt et al. (1986) Infect. Immun., V 52, pp 110-119), reacted only with T. pallidum.
• FIG. 2 shows a preliminary restriction enzyme map of the 5.4 kb insert of plasmid pMN23.
• the pMN23 insert is flanked by short dGC tails inside Pstl sites, with 5 internal Pstl sites located within the insert.
• a strategic fragment for structural analysis of the 47 kDa immunogen encoding region included a 3.85 kb Hindlll fragment; subcloning of this fragment into the Hindlll site of pBR322, however, failed to result in expression of the relevant epitope(s) when 54 ampicillin-resistant, tetracycline-sensitive, 3.85 kb Hindlll fragment-containing subclones were tested in the RICB assay using mAbs 11E3 or 8G2.
• Analogous restriction enzyme mapping of clone pMN24 revealed the presence of restriction enzyme fragments similar to those of pMN23. Thus, pMN23 and pMN24 may be identical.
• 3A contained HindiII-restricted preparations of genomic DNAs from T. pallidum, rabbit liver, and four nonpathogenic treponemes.
• lanes 3 and 8 of Fig. 3B the 3.85 kb Hindlll probe hybridized to a 3.85 kb Hindlll fragment of T. pallidum DNA and to itself; no hybridization with rabbit DNA, the DNAs of four nonpathogenic treponemes, or control DNA (lambda or pBR322) was observed.
• Multiple hybridizing bands observed in Hindlll-cleaved pMN23 (Fig. 3B, lane 8) represented the minute proportion of pMN23 not completely restricted by Hindlll treatment.
• Fig. 4 shows the results of RIP assays performed using 125 I-labeled T. pallidum and 35 S-labeled recombinant clones pMN23 and pMN20 as antigens. Solubilized antigens were immunoprecipitated using mAbs 11E3, 8G2, and 3B5. MAb 3B5, directed against a 34 kPa immunogen of T. pallidum (lane 7), was used as a control. MAbs 11E3 and 8G2 immunoprecipitated the 47 kPa immunogen from 125 I- labeled T. pallidum (Fig. 4, lanes 1, 4).
• the 48 kDa immunogen of T. pallidum may be a glycoprotein (Lukehart et al., (1982) J. Immunol., V 129, pp 833-838).
• F-pilin of E. coli may be considered a glycoprotein (containing one glucose and possibly one each of galactose and of a dideoxy hexose) (Willetts et al. (1980) Ann. Rev. Genet., V 14, pp 41-76)
• the precedent for glycoproteins in prokaryotes is poor.
• the fact that E. coli expresses a 47 kDa antigen with an identical electrophoretic mobility to the native 47 kDa immunogen of T. pallidum suggests that the 47 kDa immunogen is not a glycoprotein.
• the native 47 kDa immunogen often appears as a "47-48 kDa doublet" on Western blots of the immunogen (Marchitto et al. (1984) Infect. Immun., V 45, pp 660-666; and Norgard et al. (1984) J. Clin. Microbiol., V 20, pp 711-717).
• the appearance of the "doublet” is obscured in RIP analysis (Jones et al., (1984) J. EXP. Med., V 160, pp 1404-1420), presumably due to the intensity of the broad radioactive band appearing on the polyacrylamide gel.
• the 48 kDa component may represent unprocessed outer membrane protein precursor which is subsequently cleaved to the lower molecular weight (mature) 47 kDa form during transmembrane secretion.
• the 48 kDa component may represent some post-translational modification of the 47 kDa product.
• the recombinant DNA-derived 47 kDa immunogen has not yet been observed to exhibit the 47-48 kDa doublet phenomenon, although this may be due to undetectably low levels of 48 kDa product expressed in E. coli.
• Subcloning of the 47 kDa gene into an expression vector should help to clarify the observation.
• DNA sequencing studies also will be instrumental in establishing the primary amino acid sequence of a mature 47 kDa immunogen and any possible precursor form.
• the cloning and expression of the 47 kDa immunogen of T. pallidum in E. coli provides tools to help assess the chemical composition of the protein and the structure-function relationship of the native 47 kDa immunogen in T. pallidum, possibly leading to an increased understanding of the biology of this elusive pathogen.
• DNA encoding the 47 kDa antigen may be useful as a diagnostic DNA probe
• Purified 47 kDa immunogen can be used to re-examine, using in vitro and in vivo methods, both humoral and cell-mediated immune responses to purified antigens; this may help to further clarify the respective roles of both arms of the immune response to T. pallidum infection in the host.
• the recombinant PNA- derived immunogen also may provide the basis for an improved serological test for syphilis, potentially possessing increased specificity and simplicity over currently employed methods.
• recombinant immunogen should allow direct assessment of the immunogenic potential of the 47 kPa immunogen. Inasmuch as the 47 kPa immunogen has, at the very least, pathogen-specific epitopes, the demonstration of vaccinogenic potential for the recombinant molecule may be extended to a broad spectrum treponemal vaccine.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Molecular Biology (AREA)
• Engineering & Computer Science (AREA)
• Immunology (AREA)
• Biomedical Technology (AREA)
• Biochemistry (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Urology & Nephrology (AREA)
• Organic Chemistry (AREA)
• Hematology (AREA)
• Virology (AREA)
• Food Science & Technology (AREA)
• Genetics & Genomics (AREA)
• Gastroenterology & Hepatology (AREA)
• Biotechnology (AREA)
• Cell Biology (AREA)
• Tropical Medicine & Parasitology (AREA)
• Microbiology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Biophysics (AREA)
• Physics & Mathematics (AREA)
• Analytical Chemistry (AREA)
• General Physics & Mathematics (AREA)
• Pathology (AREA)
• Preparation Of Compounds By Using Micro-Organisms (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Peptides Or Proteins (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)

Priority Applications (3)

Applications Claiming Priority (2)

Publications (1)

Family

ID=25433526

Family Applications (1)

Country Status (11)

Cited By (4)

Families Citing this family (9)

Citations (1)

Family Cites Families (2)

• 1986
  • 1986-09-30 US US06/913,724 patent/US4868118A/en not_active Expired - Lifetime
• 1987
  • 1987-09-21 JP JP62505911A patent/JPH02500403A/ja active Pending
  • 1987-09-21 WO PCT/US1987/002403 patent/WO1988002403A1/en not_active Ceased
  • 1987-09-21 DE DE3751870T patent/DE3751870T2/de not_active Expired - Lifetime
  • 1987-09-21 CH CH2160/88A patent/CH676606A5/de not_active IP Right Cessation
  • 1987-09-21 AU AU80214/87A patent/AU8021487A/en not_active Abandoned
  • 1987-09-21 EP EP87906542A patent/EP0324774B1/en not_active Expired - Lifetime
  • 1987-09-21 AT AT87906542T patent/ATE141325T1/de not_active IP Right Cessation
  • 1987-09-23 CA CA000547633A patent/CA1336692C/en not_active Expired - Lifetime
  • 1987-09-27 IL IL84006A patent/IL84006A/xx not_active IP Right Cessation
• 1988
  • 1988-05-30 DK DK293988A patent/DK293988A/da not_active Application Discontinuation

Patent Citations (1)

Also Published As

Similar Documents

Legal Events